Malviya G, Galli F, Sonni I, Pacilio M, Signore A. Proc R Soc Med. 1910;3(Surg Sect):1C48. [PMC free article] [PubMed] [Google Scholar] 17. Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten initial cases. 1893. Clin Orthop Relat Res. 1991;(262):3C11. [PubMed] [Google Scholar] 18. Kantoff PW, Higano CS, Shore ND, et al.IMPACT Study Investigators Sipuleucel-T immunotherapy for castration-resistant prostate malignancy. N Engl J Med. 2010;363(5):411C422. [PubMed] [Google Scholar] 19. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Malignancy Inst. 2010;102(7):493C501. [PubMed] [Google Scholar] 20. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell malignancy using high-dose bolus interleukin 2. JAMA. 1994;271(12):907C913. [PubMed] [Google Scholar] 21. Sylvester RJ, van der MA, Lamm DL. Intravesical Bacillus CalmetteCGuerin reduces the risk of progression in patients with superficial bladder malignancy: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964C1970. [PubMed] [Google Scholar] 22. Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in malignancy immunotherapy. Mol Malignancy Ther. 2015;14(4):847C856. [PubMed] [Google Scholar] 23. Pennock GK, Waterfield W, Wolchok JD. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from standard treatment responses? Am J FGFR1/DDR2 inhibitor 1 Clin Oncol. 2012;35(6):606C611. [PubMed] [Google Scholar] 24. Wolchok JD, Hoos A, ODay S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Malignancy Res. 2009;15(23):7412C7420. [PubMed] [Google Scholar] 25. Jadus MR, Natividad J, Mai A, et al. Lung malignancy: a classic example of tumor escape and progression while providing opportunities for immunological intervention. Clin Dev FGFR1/DDR2 inhibitor 1 Immunol. 2012;2012:160724. [PMC free article] [PubMed] [Google Scholar] 26. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in malignancy: mechanistic basis and therapeutic strategies. Semin Malignancy Biol. 2015;35(suppl):S185CS198. [PubMed] [Google Scholar] 27. Shahani L, Singh S, Khardori NM. Immunotherapy in clinical medicine: historical perspective and current status. Med Clin North Am. 2012;96(3):421C431. ix. [PubMed] [Google Scholar] 28. Davila ML, Bouhassira DC, Park JH, et al. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int SAP155 J Hematol. 2014;99(4):361C371. [PMC free article] [PubMed] [Google Scholar] 29. Baksh K, Weber J. Immune checkpoint protein inhibition for malignancy: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin Oncol. 2015;42(3):363C377. [PubMed] [Google Scholar] 30. Pardoll DM. The blockade of immune checkpoints in malignancy immunotherapy. Nat Rev FGFR1/DDR2 inhibitor 1 Malignancy. 2012;12(4):252C264. [PMC free article] [PubMed] [Google Scholar] 31. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Malignancy Res. 2011;17(22):6958C6962. [PMC free article] [PubMed] [Google Scholar] 32. Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy. 2013;5(3):215C229. [PubMed] [Google Scholar] 33. Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol. 2015;23:32C38. [PMC free article] [PubMed] [Google Scholar] 34. Robert C, Schachter J, Long GV, et al.KEYNOTE-006 Investigators Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521C2532. [PubMed] [Google Scholar] 35. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015;33(18):2092C2099. [PMC free article] [PubMed] [Google Scholar] 36. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of malignancy treatment. Malignancy. 1981;47(1):207C214. [PubMed] [Google Scholar] 37. World Health Business . WHO Handbook for Reporting Results of Malignancy Treatment. Geneva: World Health Business; 1979. p. 45. [Google Scholar] 38. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors European Organization.
